Member in focus Rohini Kuner has been awarded the 2026 Jung Prize for Medicine

How does chronic pain develop? This is the subject of research by pharmacologist Rohini Kuner, Director of the Institute of Pharmacology at Heidelberg University’s Faculty of Medicine. She has now been awarded the Jung Prize for Medicine – one of the most highly endowed medical prizes in Europe – for her findings. Rohini Kuner has been a member of the Leopoldina since 2019.

One in five people in Europe suffers from chronic pain. It often dictates the daily lives of those affected, significantly reduces their quality of life and, in some cases, even renders them unable to work. Chronic pain is one of the greatest burdens on the healthcare system. It is not yet fully understood which molecular mechanisms cause pain to become chronic. Rohini Kuner is investigating which processes in the nervous system lead to pain being ‘learned’ and permanently stored in the body. Her research focuses on neural plasticity, i.e. the ability of nerve cells to adapt structurally and functionally. Kuner’s findings are leading to new therapeutic approaches for targeted and long-term effective treatments.

Rohini Kuner studied Pharmaceutical Biotechnology at the University of Bombay in India and obtained her PhD in 1994 at the University of Iowa in the USA. In 2005, she completed her habilitation at the Heidelberg Medical Faculty of Heidelberg University. She has held a W3 professorship in Pharmacology and Toxicology there since 2006. She has headed the Institute of Pharmacology since 2009. She is the spokesperson for the DFG Collaborative Research Centre “From Nociception to Chronic Pain: Structural and Functional Characteristics of Neural Pathways and Their Reorganisation”. Kuner has already received numerous awards for her research – including the Gottfried Wilhelm Leibniz Prize from the German Research Foundation (DFG), the most prestigious research funding award in Germany.

The Jung Prize for Medicine has been awarded by the Hamburg-based Jung Foundation for Science and Research since 1976. It is endowed with 300,000 euros. The prize honours researchers whose projects have made a significant contribution to the advancement of human medicine. The focus is on research work of particular clinical relevance that holds promise for progress in the development of new, effective therapeutic approaches.

The Leopoldina uses cookies

We use cookies on our website. Some of them are necessary (functional cookies), while others are not necessary but help us to improve our online offering and operate it economically.

You can consent to the use of non-essential cookies by clicking on the "Accept all" button or by clicking on individual settings and agreeing to them by clicking on "Accept selection".

You can access these settings at any time and deselect cookies at a later date.

Functional

These cookies are technically necessary in order to provide the following core functionalities of the website:

  • Display of the website
  • Anonymisation of IP addresses within log files
  • Status cookie consent
Comfort

In addition to necessary cookies, we also use cookies to make your use of the website more pleasant. If you accept these cookies, external media will be loaded without your further consent.

Tracking

With the help of statistics cookies, we can better customise the content and services of our website to your interests and needs. For statistics and analyses, we use the product Matomo for statistics and analyses.

External link warning

Die Nutzung dieses Teildienstes erfordert ihre Einwilligung in die Verarbeitung zusätzlicher personenbezogener Daten durch einen selbständigen Verantwortlichen: Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gelten folgende Datenschutzhinweise: https://matterport.com/de/node/44. Mit der Einwilligung durch Klick auf „Ok“ kann auch eine Übermittlung von personenbezogenen Daten in ein Land außerhalb der Europäischen Union erfolgen. Die Einwilligung ist freiwillig. Eine Ablehnung führt zu keinen Nachteilen. Eine erteilte Einwilligung kann jederzeit mit Wirkung für die Zukunft widerrufen werden.

Ich bin damit einverstanden, dass bei Nutzung dieses Teildienstes zusätzliche personenbezogene Daten verarbeitet werden. Dabei verarbeitete Datenkategorien: technische Verbindungsdaten des Serverzugriffs (IP-Adresse, Datum, Uhrzeit, abgefragte Seite, Browser-Informationen), Daten zur Erstellung von Nutzungsstatistiken und Daten über die Nutzung der Website sowie die Protokollierung von Klicks auf einzelne Elemente. Zweck der Verarbeitung: Auslieferung von Inhalten, die von Dritten bereitgestellt werden. Rechtsgrundlage für die Verarbeitung: Ihre Einwilligung nach Art. 6 (1) a DSGVO, Art. 49 DSGVO. Verantwortlicher für die Datenverarbeitung Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gilt die Datenschutzerklärung von Matterport Inc.: https://matterport.com/de/node/44.

Visit page ▸